Selective antitumoural action of pressurized mango leaf extracts against minimally and highly invasive breast cancer

2017 ◽  
Vol 8 (10) ◽  
pp. 3610-3620 ◽  
Author(s):  
M. T. Fernández-Ponce ◽  
A. López-Biedma ◽  
C. Sánchez-Quesada ◽  
L. Casas ◽  
C. Mantell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Leaf Extracts ◽  
Hormone Receptor Positive ◽  
Different Types ◽  
Mango Leaves ◽  
Antitumoral Action

Mango leaves, traditionally used to reduce inflammation, have been proved to possess antitumoral action against different types of breast cancer (hormone receptor-positive or negative).

scholarly journals Breast Cancer, Version 3.2018

2019 ◽  
Vol 17 (2) ◽  
pp. 118-126 ◽  
Author(s):  
Matthew P. Goetz ◽  
William J. Gradishar ◽  
Benjamin O. Anderson ◽  
Jame Abraham ◽  
Rebecca Aft ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Systemic Chemotherapy ◽  
Early Stage ◽  
Nccn Guidelines ◽  
Hormone Receptor Positive

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

scholarly journals Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e58483 ◽  
Author(s):  
Zsuzsanna Varga ◽  
Peter Sinn ◽  
Florian Fritzsche ◽  
Arthur von Hochstetter ◽  
Aurelia Noske ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Oncotype Dx ◽  
Test Results ◽  
Hormone Receptor Positive

scholarly journals Prediction model of low risk recurrence distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer: A validation study

2017 ◽  
Vol 28 ◽  
pp. x18-x19
Author(s):  
Y. Tsuchida ◽  
N. Hayashi ◽  
F. Omata ◽  
S. Ohde ◽  
Y. Kanada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prediction Model ◽  
Validation Study ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Recurrence Score ◽  
Low Risk ◽  
Hormone Receptor Positive ◽  
Risk Recurrence

The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients

Breast Cancer ◽  
2013 ◽  
Vol 22 (4) ◽  
pp. 406-412 ◽  
Author(s):  
Toshinao Onoda ◽  
Hideko Yamauchi ◽  
Hiroshi Yagata ◽  
Koichiro Tsugawa ◽  
Naoki Hayashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Recurrence Score ◽  
Receptor Expression ◽  
Progesterone Receptor Expression ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive

Proteinprofiling discriminates steroid hormone receptor positive and negative ductal invasive breast cancer

2005 ◽  
Vol 127 (04) ◽  
Author(s):  
F Traub ◽  
H Tammen ◽  
A Pich ◽  
P Schulz-Knappe ◽  
HH Kreipe
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Steroid Hormone ◽  
Steroid Hormone Receptor ◽  
Hormone Receptor Positive

scholarly journals Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients

2019 ◽  
Vol 301 (2) ◽  
pp. 573-583
Author(s):  
Clara Taubenhansl ◽  
Olaf Ortmann ◽  
Michael Gerken ◽  
Elisabeth C. Inwald ◽  
Monika Klinkhammer-Schalke
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Cox Regression ◽  
Distant Metastases ◽  
Free Survival ◽  
Node Positive ◽  
Hormone Receptor Positive ◽  
Kaplan Meier ◽  
Multivariable Analyses

Abstract Purpose The German guideline for breast cancer recommends using chemotherapy (CHT) in patients with hormone receptor-positive and node-positive, invasive breast cancer. The aim of this study was to analyse the effects of CHT in this patient group on overall survival (OS) and distant metastases-free survival (DMFS), especially considering the 70-year threshold. Methods 1772 patients from the clinical cancer registry Regensburg (Germany) with hormone receptor-positive and node-positive, invasive breast cancer diagnosed between 2003 and 2013 were analysed in a retrospective cohort study. OS and DMFS were evaluated by means of Kaplan–Meier and multivariable Cox-regression method. Results were further examined according to age at diagnosis. Results The comparison of 1544 patients with CHT to 228 patients without CHT showed a significant benefit for CHT regarding 5-year OS (91.3% vs. 76.8%) and 5-year DMFS (86.7% vs. 74.4%, both p < 0.001). Likewise, better OS and DMFS were seen in patients aged < 70 years using CHT compared to patients without CHT of the same age. Patients aged ≥ 70 years with CHT had a minimal benefit regarding 5-year OS compared to patients without CHT, but no advantage considering DMFS. All results were confirmed in multivariable analyses except for patients being ≥ 70 years of age. Conclusion Patients with hormone receptor-positive and node-positive, invasive breast cancer benefit from chemotherapy with regard to a significantly better overall and distant metastases-free survival, although chemotherapy use in patients aged ≥ 70 years results in a smaller benefit considering OS and no benefit considering DMFS.

scholarly journals Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
Author(s):  
Zsuzsanna Varga ◽  
Peter Sinn ◽  
Florian Fritzsche ◽  
Arthur von Hochstetter ◽  
Aurelia Noske ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Hormone Receptor ◽  
Oncotype Dx ◽  
Test Results ◽  
Hormone Receptor Positive
Sign in / Sign up

Export Citation Format

Share Document